Recent Updates
Recently added Catalysts
SLDB

Solid Biosciences Announces Appointment Ian F Smith Chairman

Thursday, June 18, 2020 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Solid Biosciences Announces Appointment Ian F Smith Chairman

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+116%
120-day peak, hindsight
Typical move
7.4%
average across 7 past catalysts
Cash runway
~21 mo
Low dilution risk
Lead asset
carmustine
Phase 3 · Lymphoma

Full Press Release Details

Solid Biosciences Announces Appointment Ian F Smith Chairman.
ShareAdd on Google
Tags: SLDB Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jun 18, 2020

Biotech snapshot

Cash runway
$378M liquidity · $18M/mo burn
~21 mo
Low dilution risk
Lead asset
carmustinePhase 3
Lymphoma →

Catalyst track record

+116%
best trade around SLDB's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for SLDB.

See every catalyst's timing & PoA →